Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

Richard Finn , Philippe Merle , Alessandro Granito , Yi-Hsiang Huang , György Bodoky , Marc Pracht (1) , Osamu Yokosuka , Olivier Rosmorduc (2) , René Gerolami (3, 4) , Chiara Caparello , Roniel Cabrera , Charissa Chang (5) , Weijing Sun , Marie-Aude Leberre , Annette Baumhauer , Gerold Meinhardt , Jordi Bruix

1 CRLCC - CRLCC Eugène Marquis
2 UPMC - Faculté de Médecine - Département d'Enseignement et de Recherche en Médecine Générale
3 Service d'hépato-gastro-entérologie [Hôpital de la Timone -APHM]
4 MEPHI - Microbes évolution phylogénie et infections
5 MSSM - Icahn School of Medicine at Mount Sinai [New York]

Domains: Life Sciences [q-bio]; Microbiology and Parasitology; Bacteriology; Life Sciences [q-bio]; Microbiology and Parasitology; Virology; Life Sciences [q-bio]; Microbiology and Parasitology; Parasitology; Life Sciences [q-bio]; Human health and pathology; Cardiology and cardiovascular system; Life Sciences [q-bio]; Human health and pathology; Emerging diseases; Life Sciences [q-bio]; Human health and pathology; Infectious diseases

Richard Finn, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, et al.. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. Journal of Hepatology, 2018, 69 (2), pp.353-358. ⟨10.1016/j.jhep.2018.04.010⟩. ⟨hal-02471037⟩